Clinical trial
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy Controls
NCT00970229 is registered in ClinicalTrials.gov with Institute for Neurodegenerative Disorders as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy Controls
- Lead sponsor
- Institute for Neurodegenerative Disorders
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2009
- Completion date
- May 31, 2015
- Enrollment
- 19 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.